- Conditions
- Non-Small Cell Lung Cancer, Epigenetic Therapy
- Interventions
- Azacitidine, Entinostat, Nivolumab, CC-486 300
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 865–888
of 3,564
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
- Interventions
- Microwave Ablation
- Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Duarte, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- ALK-positive Advanced Tumors
- Interventions
- ceritinib, warfarin, midazolam
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • San Antonio, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Proton beam therapy RT
- Drug · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, pemetrexed disodium, docetaxel
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 13
- States / cities
- Detroit, Michigan • New York, New York • Cleveland, Ohio + 3 more
- Conditions
- Lung Cancer
- Interventions
- Cisplatin, Docetaxel, Pemetrexed disodium, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Detroit, Michigan
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- pemetrexed, cisplatin, carboplatin, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- GR-MD-02, Pembrolizumab
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Lung Cancer
- Interventions
- Motexafin Gadolinium
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 7
- States / cities
- La Verne, California • Rochester, New York • Canton, Ohio + 4 more
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
- Interventions
- FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
- Drug · Combination Product
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- SGN-15, Docetaxel
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Portland, Oregon
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
- Interventions
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Drug · Combination Product
- Lead sponsor
- Marengo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- Hsp90 inhibitor AUY922, pemetrexed disodium, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Anamorelin Hydrochloride, Placebo, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
- Interventions
- AZD6750, rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pivanex, Docetaxel
- Drug
- Lead sponsor
- Titan Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 5
- States / cities
- La Verne, California • New Orleans, Louisiana • Brooklyn, New York + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Selpercatinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Stockton, California • Torrance, California + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
- Conditions
- Advanced Malignancies, Non-small Cell Lung Cancer
- Interventions
- MGCD265+erlotinib, MGCD265+docetaxel
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Durham, North Carolina • Philadelphia, Pennsylvania + 2 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 15
- States / cities
- Monterey, California • Santa Rosa, California • Colorado Springs, Colorado + 12 more
- Conditions
- Lung Neoplasms
- Interventions
- pemetrexed, gemcitabine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 5
- States / cities
- Fort Myers, Florida • Marshfield, Minnesota • Minneapolis, Minnesota + 2 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
- Interventions
- BAY2927088, Itraconazole, Carbamazepine
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed, Sarcoma - Enrollment Completed
- Interventions
- ID-LV305
- Biological
- Lead sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 7
- States / cities
- San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more